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Hypersensitivity reactions (HSRs) to paclitaxel are frequently encountered in patients receiving this antitumour drug. Administration
of histamine H1- and H2-receptor antagonists and corticosteroids has been shown to reduce significantly the risk of developing an
HSR in patients receiving taxanes. In this case report, we describe the fatal outcome of an HSR in a patient receiving paclitaxel despite
short-course premedication. The level of evidence supporting the short-course i.v. premedication schedule is challenged, as it is not
compatible with the pharmacokinetic properties of dexamethasone.
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A hypersensitivity reaction (HSR), defined as any immunological
response to a drug resulting in an adverse reaction, is a frequent
side effect during paclitaxel infusion (Zanotti and Markman, 2001).
Symptoms vary from mild pruritus to anaphylaxis (Weiss et al,
1990). The occurrence of HSRs can be influenced by administra-
tion of an appropriate premedication. Oral premedication with
dexamethasone at a dose of 20mg given orally at 12 and 6h before
infusion of paclitaxel has been shown to reduce the incidence of
paclitaxel-induced HSRs significantly (Weiss et al, 1990; Rowinsky
and Donehower, 1995; Kintzel, 2001). However, due to logistical
factors, short-course premedication with intravenously (i.v.)
administered dexamethasone given 30min prior to paclitaxel
infusion has become customary in many centres. Retrospective
analyses comparing the effectivity of both prophylactic regimens
have been performed. However, outcomes from these studies are
inconsistent. In this report, the rationale of short-course i.v.
dexamethasone is discussed at the occasion of a fatal anaphylactic
event after paclitaxel infusion with the latter premedication
regimen.
CASE REPORT
A 52-year-old male with good performance status was referred for
treatment of biopsy-proven non-small-cell lung cancer (NSCLC).
The primary lesion was located in the left upper lobe with multiple
pleural metastases and thoracoscopic invasion of the mediastinum.
The patient was offered palliative chemotherapy consisting of
paclitaxel (200mg/m
2) as a 3-hourly infusion followed by
carboplatin (area under curve 6) infusion, both as 3-weekly cycles.
Premedication consisted of i.v. administered clemastine (2mg),
ranitidine (50mg) and dexamethasone (10mg), and was given
30min prior to paclitaxel infusion. Shortly after the start of the
paclitaxel infusion, the patient complained of acute progressive
pain in his lower back, breathlessness and chest pain. He
developed general distress, followed by cardiac arrest. Cardiopul-
monary resuscitation, which included intubation and respiratory
support, was started without delay and remained unsuccessful. An
autopsy was performed confirming the presence of a stage IV
NSCLC extending beyond the parietal pleura into the adjacent soft
tissue. Additional findings included mild left ventricular hyper-
trophy and biventricular dilatation with moderate atherosclerosis
of the coronary arteries. Other causes of acute death, such as
myocardial infarction, could be excluded. The spleen and liver
were congested, consistent with fluid accumulation in the third
space.
DISCUSSION
In this report, we describe the fatal outcome of an acute-onset HSR
after paclitaxel infusion, despite administration of a widely
accepted regimen of premedication. Postmortem findings after
anaphylactic reactions and especially medication-induced anaphy-
laxis are generally nonspecific and include pulmonary congestion
and oedema. Findings indicating an immunological (allergic)
cause of death as cutaneous erythema, upper airway oedema and
pettecchial haemorrhages are rarely seen (Pumphrey and Roberts,
2000).
Paclitaxel is widely used as antitumour medication in ovarian,
breast, non-small-cell lung and other cancers. Owing to the poor
insolubility of paclitaxel, the compound requires dissolution in
Cremophor EL, a derivative of castor oil.
Although the incidence of HSR after paclitaxel infusion is
estimated to be o44 and o10% for mild and severe HSRs,
respectively, fatal outcome is rare (Weiss et al, 1990). It is known Received 28 February 2003; accepted 23 July 2003
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and are usually restricted to the first two cycles of chemotherapy.
The aetiology of paclitaxel-associated HSR is multifactorial and
several mechanisms have been postulated: (A) an IgE-mediated
mast-cell degranulation induced by paclitaxel (Weiss et al, 1990)
or Cremophor EL (Dye and Watkins, 1980; Weiss and Baker,
1987); (B) a non-IgE-mediated idiosyncratic mast-cell degranula-
tion by paclitaxel or by Cremophor EL (Gelderblom et al, 2001)
and (C) complement activation (Szebeni et al, 2001). The rapid and
overwhelming onset of the HSR as observed in our patient is not
compatible with the natural course of an IgE hypersensitivity
reaction and points towards one of the two other mechanisms.
Dexamethasone is a long-acting glucocorticoid with a biologic
half-life of approximately 48h and noticeable onset of biologic
activity after several hours (O’Sullivan et al, 1997). Dexamethasone
strongly inhibits inflammation, especially cellular-mediated im-
munity and the production or action of the local mediators of
inflammation, such as the prostaglandins and lymphokines.
Furthermore, dexamethasone reduces vascular permeability and
maintains normal vascular responsiveness to circulating vasocon-
strictor factors. Standard premedication with dexamethasone at a
dose of 20mg given orally 12 and 6h prior to paclitaxel infusion
has been shown to prevent HSR in most cases (Weiss et al, 1990;
Rowinsky and Donehower, 1995; Kintzel, 2001). Despite this
premedication schedule, grade 3/4 HSR still occur in 1–2% of
patients (Kosmidis et al, 2002).
However, this treatment regimen requires a good compliance by
the patients. To avoid rescheduling chemotherapy schemes due to
noncompliance, attention was focused on anecdotal cases in which
dexamethasone was administered shortly before paclitaxel infu-
sion. In several retrospective series, 5–20mg of dexamethasone
administered i.v. 3min before the infusion of paclitaxel showed
equal success as the oral premedication of historical cases (Parikh
et al, 1996; Bookman et al, 1997; Micha et al, 1998; Markman et al,
1999; Kintzel, 2001). These reports are in contrast with a recent
report by Kwon et al (2002), who retrospectively showed that a
single-dose i.v. corticosteroid prophylactic regimen was associated
with a significantly higher rate of HSR than the two-dose oral
corticosteroid regimen. Bearing in mind the pharmacological
properties of dexamethasone, the short-course i.v. premedication
schedule given 30min before paclitaxel infusion is unlikely to
result in an adequate level of immunosuppression during the
infusion of the drug. This may explain the results of Kwon et al.
This is confirmed by the observation that the incidence of HSRs is
not influenced by the dosage of i.v. administered dexamethasone
30min before chemotherapy infusion (Koppler et al, 2001). It is
possible that retrospective analysis and comparison of the study
cohort with historical controls bias the observed protective effect
of short-course i.v. prophylaxis by dexamethasone. A prospective
randomised study in which the oral pre-treatment regimen is
compared with the short-course i.v. administration of dexametha-
sone is preferable.
In conclusion, the fatal outcome of the paclitaxel-associated
HSR in the patient illustrates the need for continuous awareness
and questions the importance of routine i.v. premedication for
paclitaxel administration.
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